Results 191 to 200 of about 246,656 (358)

Understanding the mechanism of learning enhancement: NMDA and GABA receptor expression

, 2007
Laura Toso, Andrea Johnson, Stephanie Bissell, Robin Roberson, Daniel Abebe, Catherine Y. Spong   +5 more
openalex   +1 more source

Neuroprotective Effects of Vinpocetine and its Major Metabolite Cis‐apovincaminic Acid on NMDA‐Induced Neurotoxicity in a Rat Entorhinal Cortex Lesion Model [PDF]

, 2009
Csaba Nyakas, Klára Felszeghy, R. Szabó, Jan N. Keijser, Paul G.M. Luiten, Zsolt Szombathelyi, Károly Tihanyi   +6 more
openalex   +1 more source

Hippocampal subfield differences in people with and without recreational ketamine use: Insights from multi‐modal neuroimaging

Addiction, EarlyView.
Abstract Background and aims Recreational ketamine use has increased globally and is associated with psychiatric and cognitive concerns. The hippocampus in preclinical models shows damage and working‐memory disruption with repeated dosing. However, whether specific hippocampal subregions may differ in people with chronic ketamine use remains unclear ...
Yi‐Hsuan Liu, Chia‐Chun Hung, Marc N. Potenza, Kun‐Hsien Chou, Pei‐Lin Lee, Chu‐Chung Huang, Chiang‐Shan R. Li, Tony Szu‐Hsien Lee, Ching‐Po Lin   +8 more
wiley   +1 more source

Inhba, Homer1 and Bdnf are major targets of transcriptomic dysregulation by neurodegenerative disease-associated excitotoxic NMDA receptor signaling. [PDF]

Commun Biol
Oberländer K, Pruunsild P, Koch P, Yan J, Szafranski K, Bading H.   +5 more
europepmc   +1 more source

Inactivation of NMDA Receptors in the Ventral Tegmental Area during Cocaine Self-Administration Prevents GluA1 Upregulation but with Paradoxical Increases in Cocaine-Seeking Behavior [PDF]

, 2017
Daniel Guzman, María B. Carreira, Allyson K. Friedman, Megumi Adachi, Rachael L. Neve, Lisa M. Monteggia, Ming‐Hu Han, Christopher W. Cowan, David W. Self   +8 more
openalex   +1 more source

Brief report: Ketamine‐assisted “bridge therapy” for opioid tapering in complex cases

The American Journal on Addictions, EarlyView.
Abstract Background Opioid use disorder (OUD) presents major challenges, especially when combined with chronic pain and psychiatric comorbidities. A 25‐year‐old woman with OUD, chronic pain, and major depressive disorder underwent an 8‐week protocol of intravenous ketamine infusions (0.5 mg/kg weekly) as an adjunct to opioid tapering. Results Methadone
Mariana C. de Oliveira, Cláudia C. de Araujo Palmeira, André B. Negrão, Ziyad A. Hadi, Julia R. Arana, Rita de Cássia Ferreira Duarte, Joice L. P. da Silva, Gustavo K. Matsui, João F. D. Rapozero, Douglas H. Crispim, André Malbergier, João M. Castaldelli‐Maia   +11 more
wiley   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Novel binding mode for negative allosteric NMDA receptor modulators. [PDF]

J Gen Physiol
Lotti JS, Syrenne JT, Benton AJ, Al-Mousawi A, Cornelison LE, Trolinder CJ, Yi F, Zhang Z, Yates-Hansen CK, McClelland LJ, Bosco J, Rau AR, Clausen RP, Hansen KB.   +13 more
europepmc   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Cortical Mechanisms Contributing to Ketamine-Induced Dissociation. [PDF]

Neuroscientist
Bera K, Looger LL, Proekt A, Cichon J.
europepmc   +1 more source